Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II autologous anti-CD19 CAR-T for relapsed or refractory B-cell acute lymphoblastic leukemia
ChiCTR-OIC-16009259Phase 2Recruiting
- Sponsor
- Lu Daopei Hospital
- Start
- Sep 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Lu Daopei Hospital. Primary endpoints: Safety and Ratio of bone marrow and peripheral B leukemia cells. Started Sep 2016; status: recruiting.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on ChiCTR-OIC-16009259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009259.